Multivalent Glycopolymer Design Unlocks Antimicrobial Activity of 2-Deoxyglucose.

Sungjin Jeon, Xianjin Qin, Marjon Zamani, Ariel L Furst, Cassandra E Callmann

Abstract read

In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sungjin JeonDepartment of Chemistry, The University of Texas at Austin, Austin, USA.ORCID 0009-0002-2450-6527

Xianjin QinDepartment of Chemistry, The University of Texas at Austin, Austin, USA.

Marjon ZamaniDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA.

Ariel L FurstDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA.ORCID 0000-0001-9583-9703

Cassandra E CallmannDepartment of Chemistry, The University of Texas at Austin, Austin, USA.ORCID 0000-0003-1561-3240

Funding

TRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024

$13.1M

A.L.F. acknowledges support from a US Government Agency and the NIH New Innovator Award DP2GM154015-01NIEHS NIH HHS T32 ES007020the Cancer Prevention and Research Institute of Texas RR210050the Welch Foundation F-2093-20220331

6 · The paper itself

Abstract

With the increasing prevalence of multidrug-resistant (MDR) pathogens, last-line therapeutics such as cyclic peptides are insufficient, underscoring the need for new classes of antimicrobial compounds with distinct mechanisms of action. Here, we report a novel approach to glycan-derived antimicrobials that transforms 2-deoxyglucose (2DG), benign small molecules, into a potent antibiotic through its multivalent display as a glycopolymer. Toward this end, we synthesized a 2DG derivative amenable to ring opening metathesis polymerization (ROMP) and evaluated the impact of both spacing between 2DG and polymer backbone, as well as degree of polymerization. Shorter linkers and lower degrees of polymerization yielded the most potent antimicrobial polymer, hereafter referred to as poly2DG. Significantly, poly2DG exhibits broad-spectrum bacterial inhibition, including against MDR methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Acinetobacter baumannii, with MIC

Indexed as

Anti-Bacterial AgentsDeoxyglucosePolymersAcinetobacter baumanniiMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsDeoxyglucosePolymers2‐deoxyglucoseglycopolymersmetabolic inhibitionmultivalence

Identifiers

PMID41957856

DOI10.1002/anie.8647127

PMCPMC13159414

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.